A new drug made from antibody compounds created by UC Irvine researchers Tom Lane and Hans Keirstead has successfully completed a phase II clinical trial for treating rheumatoid arthritis. The pharmaceutical company Medarex has licensed the antibodies, which block immune-system response, to create new treatments for autoimmunity diseases. Medarex will now enter the drug, called MDX-1100, into a large-scale phase III trial, which if successful will make the drug eligible for FDA approval and consumer use. Medarex also is testing a drug made from the UCI anti-IP-10 antibodies for treating ulcerative colitis. Lane and Keirstead created the antibodies earlier this decade for studies on autoimmunity response in multiple sclerosis and spinal cord injury.
UCI discovery part of successful arthritis drug trial
A new drug made from antibody compounds created by UC Irvine researchers Tom Lane and Hans Keirstead has successfully completed…
May 26, 2009